{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T02:42:21Z","timestamp":1772073741833,"version":"3.50.1"},"reference-count":21,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:00:00Z","timestamp":1566518400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T00:00:00Z","timestamp":1566518400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Merck Switzerland"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s00280-019-03927-x","type":"journal-article","created":{"date-parts":[[2019,8,23]],"date-time":"2019-08-23T06:02:22Z","timestamp":1566540142000},"page":"881-889","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Prospective, observational practice survey of applied skin care and management of cetuximab-related skin reactions: PROSKIN study"],"prefix":"10.1007","volume":"84","author":[{"given":"Sacha I.","family":"Rothschild","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Betticher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Reinhard","family":"Zenh\u00e4usern","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandro","family":"Anchisi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Roger","family":"von Moos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Miklos","family":"Pless","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Moosmann","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Razvan A.","family":"Popescu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antonello","family":"Calderoni","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marco","family":"Dressler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Rauch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefanie","family":"Pederiva","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Regina","family":"Woelky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudia","family":"Papet","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vera","family":"B\u00fchler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markus","family":"Borner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,23]]},"reference":[{"issue":"15","key":"3927_CR1","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.2165\/11205010-000000000-00000","volume":"70","author":"JE Frampton","year":"2010","unstructured":"Frampton JE (2010) Cetuximab: a review of its use in squamous cell carcinoma of the head and neck. Drugs 70(15):1987\u20132010","journal-title":"Drugs"},{"issue":"2","key":"3927_CR2","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1007\/s40487-017-0050-6","volume":"5","author":"LM Guggina","year":"2017","unstructured":"Guggina LM, Choi AW, Choi JN (2017) EGFR inhibitors and cutaneous complications: a practical approach to management. Oncol Ther 5(2):135\u2013148","journal-title":"Oncol Ther"},{"key":"3927_CR3","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.critrevonc.2017.10.011","volume":"120","author":"P Bonomo","year":"2017","unstructured":"Bonomo P, Loi M, Desideri I et al (2017) Incidence of skin toxicity in squamous cell carcinoma of the head and neck treated with radiotherapy and cetuximab: a systematic review. Crit Rev Oncol Hematol 120:98\u2013110","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"3927_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1007\/s11523-013-0257-x","volume":"8","author":"F Petrelli","year":"2013","unstructured":"Petrelli F, Borgonovo K, Barni S (2013) The predictive role of skin rash with cetuximab and panitumumab in colorectal cancer patients: a systematic review and meta-analysis of published trials. Target Oncol 8(3):173\u2013181","journal-title":"Target Oncol"},{"issue":"2","key":"3927_CR5","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1159\/000229752","volume":"77","author":"X Su","year":"2009","unstructured":"Su X, Lacouture ME, Jia Y, Wu S (2009) Risk of high-grade skin rash in cancer patients treated with cetuximab\u2014an antibody against epidermal growth factor receptor: systemic review and meta-analysis. Oncology 77(2):124\u2013133","journal-title":"Oncology"},{"issue":"14","key":"3927_CR6","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, Kohne CH, Hitre E et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360(14):1408\u20131417","journal-title":"N Engl J Med"},{"issue":"11","key":"3927_CR7","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1056\/NEJMoa0802656","volume":"359","author":"JB Vermorken","year":"2008","unstructured":"Vermorken JB, Mesia R, Rivera F et al (2008) Platinum-based chemotherapy plus cetuximab in head and neck cancer. N Engl J Med 359(11):1116\u20131127","journal-title":"N Engl J Med"},{"issue":"10","key":"3927_CR8","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15(10):1065\u20131075","journal-title":"Lancet Oncol"},{"issue":"6","key":"3927_CR9","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1016\/j.ad.2015.01.006","volume":"106","author":"A Jaka","year":"2015","unstructured":"Jaka A, Gutierrez-Rivera A, Lopez-Pestana A et al (2015) Predictors of tumor response to cetuximab and panitumumab in 116 patients and a review of approaches to managing skin toxicity. Actas Dermo-Sifiliograficas 106(6):483\u2013492","journal-title":"Actas Dermo-Sifiliograficas"},{"key":"3927_CR10","unstructured":"European Agency for the Evaluation of Medicinal Products (EMA) Erbitux (Cetuximab) Summary of Product Characteristics (SmPC). June 2014. \n                    http:\/\/www.ema.europa.eu\n                    \n                  . Accessed 30 May 2018"},{"issue":"8","key":"3927_CR11","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","volume":"19","author":"ME Lacouture","year":"2011","unstructured":"Lacouture ME, Anadkat MJ, Bensadoun RJ et al (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19(8):1079\u20131095","journal-title":"Support Care Cancer"},{"issue":"34","key":"3927_CR12","doi-asserted-by":"publisher","first-page":"5390","DOI":"10.1200\/JCO.2007.12.6987","volume":"25","author":"A Scope","year":"2007","unstructured":"Scope A, Agero AL, Dusza SW et al (2007) Randomized double-blind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 25(34):5390\u20135396","journal-title":"J Clin Oncol"},{"issue":"4","key":"3927_CR13","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/j.jaad.2009.03.046","volume":"61","author":"A Scope","year":"2009","unstructured":"Scope A, Lieb JA, Dusza SW, Phelan DL, Myskowski PL, Saltz L, Halpern AC (2009) A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 61(4):614\u2013620","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"3927_CR14","doi-asserted-by":"publisher","first-page":"243","DOI":"10.1159\/000277430","volume":"220","author":"V Nikolaou","year":"2010","unstructured":"Nikolaou V, Stratigos A, Antoniou C, Kiagia M, Nikolaou C, Katsambas A, Syrigos K (2010) Pimecrolimus cream 1% for the treatment of papulopustular eruption related to epidermal growth factor receptor inhibitors: a case series and a literature review of therapeutic approaches. Dermatology 220(3):243\u2013248","journal-title":"Dermatology"},{"issue":"1","key":"3927_CR15","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1684\/ejd.2012.1899","volume":"23","author":"JC Jo","year":"2013","unstructured":"Jo JC, Hong YS, Kim KP et al (2013) Topical vitamin K1 may not be effective in preventing acneiform rash during cetuximab treatment in patients with metastatic colorectal cancer. Eur J Dermatol EJD 23(1):77\u201382","journal-title":"Eur J Dermatol EJD"},{"issue":"1","key":"3927_CR16","doi-asserted-by":"publisher","first-page":"62","DOI":"10.1016\/j.clcc.2013.10.001","volume":"13","author":"F Pinta","year":"2014","unstructured":"Pinta F, Ponzetti A, Spadi R et al (2014) Pilot clinical trial on the efficacy of prophylactic use of vitamin K1-based cream (Vigorskin) to prevent cetuximab-induced skin rash in patients with metastatic colorectal cancer. Clin Colorectal Cancer 13(1):62\u201367","journal-title":"Clin Colorectal Cancer"},{"issue":"4","key":"3927_CR17","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1111\/j.1468-3083.2009.03446.x","volume":"24","author":"J Ocvirk","year":"2010","unstructured":"Ocvirk J, Cencelj S (2010) Management of cutaneous side-effects of cetuximab therapy in patients with metastatic colorectal cancer. J Eur Acad Dermatol Venereol 24(4):453\u2013459","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"2","key":"3927_CR18","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1634\/theoncologist.2010-0298","volume":"16","author":"C Pinto","year":"2011","unstructured":"Pinto C, Barone CA, Girolomoni G, Russi EG, Merlano MC, Ferrari D, Maiello E (2011) Management of skin toxicity associated with cetuximab treatment in combination with chemotherapy or radiotherapy. Oncologist 16(2):228\u2013238","journal-title":"Oncologist"},{"issue":"4","key":"3927_CR19","doi-asserted-by":"publisher","first-page":"407","DOI":"10.1097\/COC.0000000000000291","volume":"39","author":"C Pinto","year":"2016","unstructured":"Pinto C, Barone CA, Girolomoni G, Russi EG, Merlano MC, Ferrari D, Maiello E (2016) Management of skin reactions during cetuximab treatment in association with chemotherapy or radiotherapy: update of the italian expert recommendations. Am J Clin Oncol 39(4):407\u2013415","journal-title":"Am J Clin Oncol"},{"issue":"18","key":"3927_CR20","doi-asserted-by":"publisher","first-page":"3169","DOI":"10.1016\/j.ejca.2010.03.008","volume":"46","author":"J Duffour","year":"2010","unstructured":"Duffour J, Thezenas S, Dereure O et al (2010) Inter-observer agreement between dermatologists and oncologists in assessing dermatological toxicities in patients with metastatic colorectal cancer treated by cetuximab-based chemotherapies: a pilot comparative study. Eur J Cancer 46(18):3169\u20133174","journal-title":"Eur J Cancer"},{"issue":"8","key":"3927_CR21","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1136\/jech.2003.008466","volume":"58","author":"M Delgado-Rodriguez","year":"2004","unstructured":"Delgado-Rodriguez M, Llorca J (2004) Bias. J Epidemiol Community Health 58(8):635\u2013641","journal-title":"J Epidemiol Community Health"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-019-03927-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-019-03927-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,21]],"date-time":"2020-08-21T23:10:46Z","timestamp":1598051446000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-019-03927-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,23]]},"references-count":21,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["3927"],"URL":"https:\/\/doi.org\/10.1007\/s00280-019-03927-x","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,23]]},"assertion":[{"value":"23 July 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 August 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The study was funded by Merck (Switzerland) AG, Zug, an affiliate of Merck KGaA, Darmstadt, Germany. SIR has received honoraria for advisory boards (paid to the institution) from Merck and research funding from Merck. RVM has participated in advisory boards of Merck and Amgen and received speaker honoraria from Amgen and Merck. PM has participated in an advisory board of Merck. VB is a full-time employee at Merck (Switzerland) AG, Zug. The other authors declare no competing interests. The authors confirm they have full control of all primary data and agree to allow the journal to review their data if requested.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"This study was conducted in accordance with the protocol, the ethical principles laid down in the Declaration of Helsinki, International Council for Harmonization of Technical Requirements for Pharmaceuticals for Human Use and Good Clinical Practice (ICH GCP), guidelines and applicable regulatory requirements. The protocol, ICF, any other materials provided to the patients, and further requested information were submitted to the IEC\/IRB and the competent authority. The regulatory application or submission for regulatory approval was made by the sponsor or designee as required by national law. The competent authority and the IEC\/IRB were notified of the end of the study in accordance with local regulations.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical considerations"}}]}}